Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 118,932

Document Document Title
WO/2016/170064A1
The present invention provides imidazotriazinones of formula (I) as PDEl inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.  
WO/2016/172333A1
The present disclosure relates to solid state forms of Perampanel, processes for preparation thereof and pharmaceutical compositions thereof.  
WO/2016/169454A1
A nerve growth factor composition and a powder injection. The nerve growth factor composition comprises the following components: 10μg/mL to 100μg/mL of nerve growth factor, 10mg/mL to 80mg/mL of disaccharide stabilizer, 0mg/mL to 30mg...  
WO/2016/171549A1
The present invention describes a compound for use in treating or preventing glutamate excitotoxicity and/or tauopathy in a subject, preferably a disorder selected from the group of epilepsy, spinal cord injury, stroke, traumatic brain i...  
WO/2016/170009A1
The present invention relates to novel aminoindazolyl derivative compounds of Formula(I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav1.7 AND to compositions con...  
WO/2016/166684A1
The present invention relates to compounds of the general form (I). The present invention relates to new substituted diazepino-indole derivatives of the general formula (I), and to pharmaceutically acceptable salts thereof, as well as to...  
WO/2016/165770A1
The present invention refers to a 4-phenylbutyric acid derivative of Formula (1), wherein Y is selected from 0 or H2; R1 is selected from N2 or H; R2 is a radical of an amino acid, a salicylic acid, a 4- phenylbutyric acid, a catechol, o...  
WO/2016/168757A1
This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversio...  
WO/2016/168450A1
The present invention provides a compound having the structure: wherein X is C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, cyano, aryl, heteroaryl, alkylaryl, alkylheteroaryl, alkenylaryl, alkenylheteroaryl, alkynylaryl, alkynylheteroary...  
WO/2016/167365A1
Provided is a marker for determining a mental disease, which can be used for an objective diagnosis of a mental disease. A marker for determining a metal disease, which comprises at least one enterobacterium selected from those belonging...  
WO/2016/166679A1
The present invention concerns an acetylcholinesterase inhibitor for use in the treatment or prevention of side effects caused by the administration of an antipsychotic agent in a patient suffering from psychiatric disorders associated w...  
WO/2016/164977A1
The present specification teaches generally a method for the treatment or prophylaxis of a male-biased neurological disorder in male subjects.  
WO/2016/167263A1
In a non-limiting embodiment, a pharmaceutical composition for the prevention and/or treatment of atopic dermatitis is provided, the pharmaceutical composition containing an IL-31 antagonist as an active ingredient, wherein 0.1-1000 mg/b...  
WO/2016/168615A1
Disclosed are methods of treating or preventing demyelination in a mammal, the method comprising administering to the mammal a (1) thrombin inhibitor or (2) compound that stimulates astrocytes in the mammal to (i) release a thrombin inhi...  
WO/2016/167944A2
The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyal...  
WO/2016/168197A1
Compositions and methods for improved delivery of active agents to the brain are provided. The compositions typically include a nanocarrier, such as a polymeric nanoparticle, liposome, or nanolipagel or are in the form of a conjugate. Th...  
WO/2016/167528A1
The present invention relates to a method for converting human fibroblasts into neural stem cells and, more specifically, to a method for directly converting human fibroblasts into neural stem cells using only a combination of small mole...  
WO/2016/165101A1
The present invention provides a peptide with sequence of DEAQETAVSSHEQD, a fragment of rabbit-α1 antiproteinase F, and its derivatives DEAQETAVSSHEQ and QETACSSHEQD, which significantly inhibit serum-borne HCV replication in hADSC and ...  
WO/2016/168580A1
Bolaamphiphilic compounds are provided according to formula (I); where HG1, HG2 and L1 are as defined herein. Provided bolaamphiphilic compounds and the pharmaceutical compositions thereof are useful for delivering GDNF or NGF into anima...  
WO/2016/166078A1
The invention relates to pyridopyrimidinone compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein X, R, R2, R3, R4, R5 and R6 are as defined herein, as well as pharmaceutical compositions comprising such compound...  
WO/2016/167345A1
The present invention provides a transdermal patch provided with a support and an adhesive layer layered on the support, the adhesive layer including ropinirole or a pharmacologically acceptable salt thereof, an organic amine or an acid ...  
WO/2016/168760A1
This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversio...  
WO/2016/166565A1
The invention relates to the use of a composition from a plant extract of Withania somnifera, to prevent, treat of delay the progression of α-synucleinopathies, including Parkinson disease.  
WO/2016/168658A1
In some aspects, the disclosure relates to the reactivation of inactive X chromosomes (Xi). In some embodiments, the disclosure provides compositions and methods for the reactivation of inactive X chromosomes. In some embodiments, the co...  
WO/2016/167385A1
The present invention relates to a composition for preventing or treating Alzheimer's disease comprising lycopodiella cernua extract or a compound isolated therefrom. The lycopodiella cernua extract or the compound isolated therefrom has...  
WO/2016/167318A1
Provided are: a memory-improving agent and memory-improving composition containing as an active ingredient a compound that is an inverse agonist of opioid δ receptors, a pharmacologically acceptable salt thereof, or a solvate of these; ...  
WO/2016/168768A3
The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, ...  
WO/2016/168598A1
The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6 and HDAC11, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerativ...  
WO/2016/165014A1
The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal ad...  
WO/2016/167372A1
Provided is a method for producing cerebral cortex neurons from pluripotent stem cells. Provided is a method for producing cerebral cortex neurons from pluripotent stem cells, including: (i) a step for carrying out suspension culture of ...  
WO/2016/164218A1
The present application provides a method for treating patients in need of psychiatric treatment, wherein said patient is being treated with the 3-month formulation of paliperidone palmitate and fails to take the next scheduled dose of t...  
WO/2016/164685A1
Neuroprotective compositions, methods of making the same, and methods of using the same, are disclosed.  
WO/2016/162706A1
Our invention relates to novel enantiomer derivatives of 8-hydroxyquinoline derivatives with general formula (I) and (II) and the synthesis thereof and pharmaceutically acceptable salts and metal complexes and thereof, and the medicinal ...  
WO/2016/162246A1
The present invention relates to the use of glucomoringin (GMG) and of the corresponding isothiocyanate derivative glucomoringin des-thioglucoside (GMG-ITC) as modulators of peripheral pain with specific reference to that linked with dia...  
WO/2016/164763A1
Described herein are deuterium-enriched neuroactive steroids of the Formula (II) or a pharmaceutically acceptable salt thereof; wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, Rlla, Rllb, R12a, R12b, R16a, R16b, R17, R19, Ra, and Rb and su...  
WO/2016/164295A3
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1. Formula (I).  
WO/2016/164763A8
Described herein are deuterium-enriched neuroactive steroids of the Formula (II) or a pharmaceutically acceptable salt thereof; wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, Rlla, Rllb, R12a, R12b, R16a, R16b, R17, R19, Ra, and Rb and su...  
WO/2016/162821A3
This invention relates to a medicament. It also relates to a nutritional supplement. More particularly it relates to a medicament and to a nutritional supplement, which are extracts from a plant or a combination of plants. The extract ac...  
WO/2016/164768A1
As disclosed herein, stapled peptides targeting the interaction interface between proteins that maintain the integrity of Wiskott-Aldrich syndrome protein family member 3 (WASF3) leads to destabilization of WASF3 and suppression of invas...  
WO/2016/163912A1
The invention relates to medicine, and more particularly to neurosurgery and trauma surgery, and can be used for stimulating nerve regeneration through the use of a gene therapeutic construct which codes for vascular endothelial growth f...  
WO/2016/162506A1
The present invention relates to a composition that comprises the peptide QBP for use in the inhibition of memory consolidation, after a trauma, more preferably in Post-Traumatic Stress Disorder or related diseases.  
WO/2016/164521A1
The present invention relates to the treatment and prevention of movement disorders with the administration of one or more propionyl-CoA precursors.  
WO/2016/162870A1
Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Va...  
WO/2016/164642A1
Provided herein are compositions and methods for the viral gene therapy (e.g., AAV-directed gene therapy) of cholesterol storage diseases or disorders, such as Niemann-Pick disease, Type C.  
WO/2016/162706A9
Our invention relates to novel enantiomer derivatives of 8-hydroxyquinoline derivatives with general formula (I) and (II) and the synthesis thereof and pharmaceutically acceptable salts and metal complexes and thereof, and the medicinal ...  
WO/2016/162821A2
This invention relates to a medicament. It also relates to a nutritional supplement. More particularly it relates to a medicament and to a nutritional supplement, which are extracts from a plant or a combination of plants. The extract ac...  
WO/2016/161055A2
In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. ...  
WO/2016/161388A1
Provided herein are self-delivering oligonucleotides that are characterized by efficient RISC entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distrib...  
WO/2016/160574A2
The application relates to novel compounds and their use in treating and preventing diseases and conditions mediated by modulation of voltage-gated sodium channels. Novel aryl- and heteroaryl- pyrrolidine-2-carboxamide compounds and phar...  
WO/2016/160715A1
The present invention provides a method of treating a patient suffering from addiction, having the steps of administering to the patient a controlled release composition comprising an opioid antagonist; and coaching the patient. This sim...  

Matches 101 - 150 out of 118,932